Compare GCTK & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCTK | ENSC |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4M | 1.7M |
| IPO Year | 2011 | N/A |
| Metric | GCTK | ENSC |
|---|---|---|
| Price | $0.81 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 217.2K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 31.22 | N/A |
| Revenue | ★ $589,462.00 | N/A |
| Revenue This Year | N/A | $55.01 |
| Revenue Next Year | N/A | $1,033.97 |
| P/E Ratio | $0.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.09 | $0.31 |
| 52 Week High | $15.90 | $2.75 |
| Indicator | GCTK | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 39.10 |
| Support Level | $0.64 | $0.31 |
| Resistance Level | $1.02 | $0.63 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 23.08 | 22.62 |
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.